Einträge von Bähr, Oliver auf dem Publikationsserver

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Weller, Johannes , Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert , Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich und Schäfer, Niklas (2019) Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 20 (10), S. 1444-1453. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter , Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich und Glas, Martin (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. Journal of Cancer Research and Clinical Oncology 144 (8), S. 1581-1589. Volltext nicht vorhanden.

Weller, Michael, Tabatabai, Ghazaleh, Kästner, Bärbel, Felsberg, Jörg, Steinbach, Joachim P., Wick, Antje, Schnell, Oliver, Hau, Peter, Herrlinger, Ulrich, Sabel, Michael C., Wirsching, Hans-Georg, Ketter, Ralf, Bähr, Oliver, Platten, Michael , Tonn, Jörg C., Schlegel, Uwe, Marosi, Christine, Goldbrunner, Roland, Stupp, Roger, Homicsko, Krisztian, Pichler, Josef, Nikkhah, Guido, Meixensberger, Jürgen, Vajkoczy, Peter, Kollias, Spyros, Hüsing, Johannes, Reifenberger, Guido und Wick, Wolfgang (2015) MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research 21 (9), S. 2057-2064. Volltext nicht vorhanden.